Covered recipient · General Payments record
JOHN COZART
General Payments · PY2018–2024
$5,783.30
- Reported across 413 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $538.57 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $260.16 | 19 |
| Gilead Sciences, Inc. | $85.37 | 4 |
| PFIZER INC. | $76.03 | 5 |
| Celgene Corporation | $49.57 | 3 |
| Lilly USA, LLC | $19.57 | 1 |
| Mauna Kea Technologies, Inc. | $17.35 | 1 |
| Madrigal Pharmaceuticals | $16.08 | 1 |
| Merck Sharp & Dohme Corporation | $14.44 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $11.81 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511584 | CMS |
| ABBVIE INC. | $8.65 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511586 | CMS |
| ABBVIE INC. | $9.20 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511588 | CMS |
| ABBVIE INC. | $12.94 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511590 | CMS |
| ABBVIE INC. | $13.88 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511592 | CMS |
| ABBVIE INC. | $12.76 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511594 | CMS |
| ABBVIE INC. | $15.23 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511596 | CMS |
| ABBVIE INC. | $10.32 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511598 | CMS |
| ABBVIE INC. | $29.82 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511600 | CMS |
| ABBVIE INC. | $17.71 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511602 | CMS |
| ABBVIE INC. | $12.47 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511604 | CMS |
| ABBVIE INC. | $14.29 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511606 | CMS |
| ABBVIE INC. | $11.68 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511608 | CMS |
| ABBVIE INC. | $24.89 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511610 | CMS |
| ABBVIE INC. | $12.08 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511612 | CMS |
| ABBVIE INC. | $14.53 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511614 | CMS |
| ABBVIE INC. | $11.72 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511616 | CMS |
| ABBVIE INC. | $12.55 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511618 | CMS |
| ABBVIE INC. | $3.63 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103511620 | CMS |
| Celgene Corporation | $17.39 | 04/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101118211 | CMS |
| Celgene Corporation | $14.64 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101118213 | CMS |
| Celgene Corporation | $17.54 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101118215 | CMS |
| Gilead Sciences, Inc. | $19.69 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133735833 | CMS |
| Gilead Sciences, Inc. | $20.42 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133735835 | CMS |
| Gilead Sciences, Inc. | $23.36 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133735837 | CMS |
| Gilead Sciences, Inc. | $21.90 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133735839 | CMS |
| Lilly USA, LLC | $19.57 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135053840 | CMS |
| Madrigal Pharmaceuticals | $16.08 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144163891 | CMS |
| Mauna Kea Technologies, Inc. | $17.35 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151446682 | CMS |
| Merck Sharp & Dohme LLC | $14.44 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141819715 | CMS |
| PFIZER INC. | $14.68 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131358162 | CMS |
| PFIZER INC. | $13.61 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131669248 | CMS |
| PFIZER INC. | $14.97 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131844776 | CMS |
| PFIZER INC. | $18.13 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131987531 | CMS |
| PFIZER INC. | $14.64 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132086426 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.